These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria. Perraut R, Varela ML, Joos C, Diouf B, Sokhna C, Mbengue B, Tall A, Loucoubar C, Touré A, Mercereau-Puijalon O. Vaccine; 2017 Dec 04; 35(48 Pt B):6720-6726. PubMed ID: 29042203 [Abstract] [Full Text] [Related]
24. Evaluation of Naturally Acquired Antibody Responses to Two Variant Forms of Plasmodium vivax Apical Membrane Antigen-1 in Individuals Living in Areas of Low and Unstable Malaria Transmission of Iran. Salavatifar M, Zakeri S, Abouie Mehrizi A, Mirkhazemi S, Dinparast Djadid N. Arch Iran Med; 2015 Dec 04; 18(12):834-43. PubMed ID: 26621016 [Abstract] [Full Text] [Related]
25. Antibody response dynamics to the Plasmodium falciparum conserved vaccine candidate antigen, merozoite surface protein-1 C-terminal 19kD (MSP1-19kD), in Peruvians exposed to hypoendemic malaria transmission. Torres KJ, Clark EH, Hernandez JN, Soto-Cornejo KE, Gamboa D, Branch OH. Malar J; 2008 Sep 09; 7():173. PubMed ID: 18782451 [Abstract] [Full Text] [Related]
32. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice. Mehrizi AA, Rezvani N, Zakeri S, Gholami A, Babaeekhou L. Med Microbiol Immunol; 2018 Apr 09; 207(2):151-166. PubMed ID: 29397427 [Abstract] [Full Text] [Related]
33. Identification of cultivation condition to produce correctly folded form of a malaria vaccine based on Plasmodium falciparum merozoite surface protein-1 in Escherichia coli. Mazumdar S, Sachdeva S, Chauhan VS, Yazdani SS. Bioprocess Biosyst Eng; 2010 Aug 09; 33(6):719-30. PubMed ID: 19921275 [Abstract] [Full Text] [Related]
34. IgG antibody profile to c-terminal region of Plasmodium vivax merozoite surface protein-1 in Thai individuals exposed to malaria. Pitabut N, Panichakorn J, Mahakunkijcharoen Y, Hirunpetcharat C, Looareesuwan S, Khusmith S. Southeast Asian J Trop Med Public Health; 2007 Jan 09; 38(1):1-7. PubMed ID: 17539238 [Abstract] [Full Text] [Related]
36. Cross-sectional study of specific antibodies to a polymorphic Plasmodium falciparum antigen and of parasite antigen genotypes in school children on the slope of Mount Cameroon. Kimbi HK, Tetteh KK, Polley SD, Conway DJ. Trans R Soc Trop Med Hyg; 2004 May 09; 98(5):284-9. PubMed ID: 15109551 [Abstract] [Full Text] [Related]
37. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175. Chitnis CE, Mukherjee P, Mehta S, Yazdani SS, Dhawan S, Shakri AR, Bhardwaj R, Gupta PK, Hans D, Mazumdar S, Singh B, Kumar S, Pandey G, Parulekar V, Imbault N, Shivyogi P, Godbole G, Mohan K, Leroy O, Singh K, Chauhan VS. PLoS One; 2015 May 09; 10(4):e0117820. PubMed ID: 25927360 [Abstract] [Full Text] [Related]
38. Effect of transmission intensity and age on subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage antigens. Noland GS, Jansen P, Vulule JM, Park GS, Ondigo BN, Kazura JW, Moormann AM, John CC. Acta Trop; 2015 Feb 09; 142():47-56. PubMed ID: 25446174 [Abstract] [Full Text] [Related]